Concepedia

Author

Mohini Varughese

The Christie NHS Foundation Trust

Also Known As

M.A. Varughese, Mohini A. Varughese, Mohini Anna Varughese, Mohini Varughese, Nicola Cox, Robert Jones, Varughese, Mohini

32

Publications

1.9K

Citations

14

H-Index

19

Concepts

All Affiliations

The Christie NHS Foundation TrustInstitute of Cancer ResearchMusgrove Park HospitalUniversity College LondonSt James's University Hospital
MV

About

Mohini Varughese is an author at The Christie NHS Foundation Trust specializing in medicine, pathology, and oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

5

5

490

2

Pathology

4

4

461

3

Pharmacology

1

1

45

4

Surgical Oncology

1

1

29

5

Cancer Genetics

1

1

292

Mohini Varughese

×

14

Publications

1.7K

Citations

13

H-Index

YearCitations

Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial

Joaquı́n Mateo, Núria Porta, Diletta Bianchini,

The Lancet Oncology

2019

632

Genomics of lethal prostate cancer at diagnosis and castration resistance

Joaquı́n Mateo, George Seed, Cláudia Bertan,

Journal of Clinical Investigation

2019

292

6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial

Helena Earl, Louise Hiller, Anne-Laure Vallier,

The Lancet

2019

277

Quality of Life After Bladder Cancer: A Cross-sectional Survey of Patient-reported Outcomes

James W.F. Catto, Amy Downing, Samantha J. Mason,

European Urology

2021

152

Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)

Thomas Bachelot, Eva Ciruelos, Fabio Puglisi,

Annals of Oncology

2019

111

Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial

Janet E. Brown, Kara‐Louise Royle, Walter M. Gregory,

The Lancet Oncology

2023

76

TOPARP-B: A phase II randomized trial of the poly(ADP)-ribose polymerase (PARP) inhibitor olaparib for metastatic castration resistant prostate cancers (mCRPC) with DNA damage repair (DDR) alterations.

Joaquı́n Mateo, Núria Porta, Ursula McGovern,

Journal of Clinical Oncology

2019

45

Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial

Chris Parker, Noel W. Clarke, Adrian Cook,

The Lancet

2024

43

Treatment Allocation and Survival in Patients Diagnosed with Nonmetastatic Muscle-invasive Bladder Cancer: An Analysis of a National Patient Cohort in England

Joseph John, Mohini Varughese, Nicola Cooper,

European Urology Focus

2020

29

The impact of the 21-gene assay on adjuvant treatment decisions in oestrogen receptor-positive early breast cancer: a prospective study

Anna Kuchel, Tim Robinson, Charles Comins,

British Journal of Cancer

2016

26

Page 1